Inhibitors of c-Met and uses thereof

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

W is —S—;

L A is selected from

R A is selected from:

each of R A2 and R A6 is, independently, selected from hydrogen or halogen;

each of R A3 and R A5 is, independently, R Ar ;

R A4 is —OH, —B(OR*) 2 , —SR*, —N(R*) 2 , —N(R*)C(O)R*, —N(R*)C(O)N(R*) 2 , —N(R*)C(O)OR*, —N(R*)N(R*)C(O)R*, —N(R*)N(R*)C(O)N(R*) 2 , —N(R*)N(R*)C(O)OR * , —N(R*)S(O) 2 N(R*) 2 , —N(R*)S(O) 2 R * , —C(O)OR*, —C(O)N(R*) 2 ;

L B is a covalent bond or —N(R*)—;

R B is a 6-10 membered aryl ring; a 3-7 membered carbocyclic ring, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each of said aryl, heteroaryl, or heterocyclyl rings is optionally substituted with up to five independent occurrences of R Ar ;

each R Ar is, independently, selected from halogen, —R o , —OR o , —SR o , —OC(O)(C 1-8 aliphatic), Ph optionally substituted with up to five independent occurrences of —R o , —CH 2 (Ph) optionally substituted with up to five independent occurrences of —R o , —(CH 2 ) y (Ph) optionally substituted with up to five independent occurrences of —R o , —NO 2 , —CN, —N(R o ) 2 , —NR o C(O)R o , —NR o C(O)N(R o ) 2 , —NR o C(O)OR o , —NR o NR o C(O)R o , —NR o NR o C(O)N(R o ) 2 , —NR o NR o C(O)OR o , —C(O)CH 2 C(O)R o , —C(O)OR o , —C(O)R o , —C(O)N(R o ) 2 , —OC(O)N(R o ) 2 , —S(O) 2 R o , —S(O) 2 N(R o ) 2 , —S(O)R o , —NR o S(O) 2 N(R o ) 2 , —NR o S(O) 2 R o , —C(S)N(R o ) 2 , —C(NH)N(R o ) 2 , and —(CH 2 ) y NHC(O)R o , wherein y is 1 to 4; or two adjacent R Ar groups taken together are 1,2-methylenedioxy or 1,2-ethylenedioxy;

each R ++ is, independently, hydrogen or C 1-4 aliphatic;

each R* is, independently, hydrogen or C 1-8 aliphatic optionally substituted with up to five independent occurrences of —NH 2 , —NH(C 1-4 aliphatic), —N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, —OH, —O(C 1-4 aliphatic), —NO 2 , —CN, —C(O)OH, —C(O)O(C 1-4 aliphatic), —C(O)NH 2 , —C(O)NH(C 1-4 aliphatic), —C(O)N(C 1-4 aliphatic) 2 , —O(halo(C 1-4 aliphatic)), or halo(C 1-4 aliphatic); or two R* on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring having 1-3heteroatoms independently selected from nitrogen, oxygen, and sulfur; and

each R o is, independently, hydrogen, optionally substituted C 1-6 aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, —Ph, or —O(Ph), wherein each substituent of said optionally substituted aliphatic of R o is, independently, —NH 2 , —NH(C 1-4 aliphatic), —N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, —OH, —O(C 1-4 aliphatic), —NO 2 , —CN, —C(O)OH, —C(O)O(C 1-4 aliphatic), —C(O)NH 2 , —C(O)NH(C 1-4 aliphatic), —C(O)N(C 1-4 aliphatic) 2 , —O(halo(C 1-4 aliphatic)), or halo(C 1-4 aliphatic); or two R o on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

2. The compound according to claim 1 , wherein R B is selected from the group consisting of:

wherein each of R B1 and R B2 is, independently, hydrogen or R Ar .

3. The compound according to claim 1 , wherein L B R B is selected from:

4. A compound according to claim 1 selected from

5. A pharmaceutical composition comprising a compound according to any one of compounds 30 to 33 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

6. A method of treating or lessening the severity of a proliferative disorder in a patient comprising the step of administering to said patient a therapeutically effective dose of a compound according to any one of compounds 30 to 33, or a composition comprising said compound, wherein said proliferative disorder is gastric adenocarcinoma, gliobastoma, renal cancer, small cell lung carcinoma, colon cancer, colorectal cancer, prostate cancer, brain cancer, liver cancer, pancreatic cancer, breast cancer, or a myeloproliferative disorder.